Inhibitors of the BMP signaling pathway
The present invention provides small molecule inhibitors of BMP signaling. These compounds may be used to modulate cell growth, differentiation, proliferation, and apoptosis, and thus may be useful for treating diseases or conditions associated with BMP signaling, including inflammation, cardiovascular disease, hematological disease, cancer, and bone disorders, as well as for modulating cellular differentiation and/or proliferation.
1. A compound having a structure of Formula I:
wherein
X and Y are each N;
Z is CR 3 ;
Ar is substituted or unsubstituted phenyl;
L 1 is absent or selected from substituted or unsubstituted alkyl and heteroalkyl;
A and B are both CR 16 ;
E and F are both CR 5 and both occurrences of R 5 taken together with E and F form a substituted or unsubstituted 5- or 6-membered cycloalkyl, heterocycloalkyl, aryl, or heteroaryl ring;
R 3 is selected from H and substituted or unsubstituted alkyl;
R 4 is selected from H and substituted or unsubstituted alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, acyl, carboxyl, ester, hydroxyl, alkoxyl, alkylthio, acyloxy, amino, acylamino, carbamate, amido, amidino, sulfonyl, sulfoxido, sulfamoyl, or sulfonamido;
R 15 , independently for each occurrence, is selected from H and substituted or unsubstituted alkyl, cycloalkyl, heterocyclyl, cycloalkylalkyl, heterocyclylalkyl, halogen, acylamino, carbamate, cyano, sulfonyl, sulfoxido, sulfamoyl, or sulfonamido;
R 16 , independently for each occurrence, is absent or is selected from H and substituted or unsubstituted alkyl, alkenyl, alkynyl, aralkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, heteroaralkyl, cycloalkylalkyl, heterocyclylalkyl, halogen, acyl, carboxyl, ester, hydroxyl, alkoxyl, alkylthio, acyloxy, amino, acylamino, carbamate, amido, amidino, cyano, sulfonyl, sulfoxido, sulfamoyl, or sulfonamido,
or a pharmaceutically acceptable salt or ester thereof.
2. The compound of claim 1 , wherein A and B are each CH.
3. The compound of claim 1 or 2 , wherein both instances of R 5 taken together with E and F form a 6-membered ring.
4. The compound of claim 3 , wherein E and F together represent the group
wherein R 40 is absent or represents from 1-4 substituents selected from substituted or unsubstituted alkyl, cycloalkyl, halogen, acylamino, carbamate, cyano, sulfonyl, sulfoxido, sulfamoyl, or sulfonamido.
5. The compound of claim 1 or 2 , wherein L 1 has a structure
wherein
Q is selected from CR 10 R 11 , NR 12 , O, S, S(O), and SO 2 ; and
R 10 and R 11 , independently for each occurrence, are selected from H and substituted or unsubstituted alkyl, cycloalkyl, heterocyclyl, cycloalkylalkyl, heterocyclylalkyl, amino, acylamino, carbamate, amido, amidino, cyano, sulfonyl, sulfoxido, sulfamoyl, or sulfonamido;
R 12 selected from H and substituted or unsubstituted alkyl, cycloalkyl, heterocyclyl, heterocyclylalkyl, amino, acylamino, carbamate, amido, amidino, sulfonyl, sulfamoyl, or sulfonamido and
n is an integer from 0-4.
6. The compound of claim 1 or 2 , wherein R 4 is selected from
wherein
W is absent or is C(R 21 ) 2 , O, or NR 21 ;
R 20 is absent or is selected from substituted or unsubstituted alkyl, aralkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, heteroaralkyl, cycloalkylalkyl, heterocyclylalkyl, acyl, sulfonyl, sulfoxido, sulfamoyl, and sulfonamido; and
R 21 , independently for each occurrence, is selected from H and substituted or unsubstituted alkyl, aralkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, heteroaralkyl, cycloalkylalkyl, heterocyclylalkyl, acyl, sulfonyl, sulfamoyl, or sulfonamido.
7. The compound of claim 1 or 2 , wherein L 1 is disposed on the para-position of Ar relative to the bicyclic core .
8. A pharmaceutical composition comprising a compound of claim 1 or 2 and a pharmaceutically acceptable excipient or solvent.